Sofosbuvir/velpatasvir for 12  weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis

Hepatitis C virus (HCV) infection is a global health challenge with an estimated 71 million individuals infected worldwide.1 The disease burden of HCV infection is due to progression of chronic liver disease, which can lead to cirrhosis, liver failure, hepatocellular carcinoma, and death. Chronic HCV infection is also independently associated with the development of renal impairment referred to as chronic kidney disease (CKD) and has been shown to be more prevalent in patients with renal disease.

Source: Journal of Hepatology - June 9, 2019 Category: Gastroenterology Authors: Sergio M. Borgia, Janet Dearden, Eric M. Yoshida, Stephen D. Shafran, Ashley Brown, Ziv Ben-Ari, Matthew E. Cramp, Curtis Cooper, Matthew Foxton, Conrado Fernandez Rodriguez, Rafael Esteban, Robert Hyland, Sophia Lu, Brian J. Kirby, Amy Meng, Svetlana Mar Tags: Research Article Source Type: research